Figure 3.

C16:0 inhibits CRC cell migration, invasion and intraperitoneal dissemination by decreasing membrane fluidity. A, Fluorescence polarization of CAF-CM/C16:0-treated DLD1 cells. #, $ indicates comparisons with the corresponding control groups. n=3. B, Wound healing assay of DLD1 cells incubated with CAF-CM and treated with the indicated compounds as detected by IncuCyte ZOOM. n=3. C, Quantification of the wounding rates of DLD1 cells in Fig. 3B. #, $ indicates comparisons with the corresponding control groups. Wound width was normalized to the initial width when the wound was created. n=3. D, Crystal violet staining was used to quantify DLD1/HCT116 cell Transwell invasion after 24 h of exposure to CAF-CM and treatment with the indicated compounds. n=3. E, The number of crystal violet-stained cells among DLD1 cells that invaded Transwell membranes is shown in Fig. 3D. n=3. F, Animals from each test group were bioimaged (Xenogen IVIS system) by detecting the luciferase emission spectrum at 2 weeks after i.p. injection to visualize the progression of tumor growth in the peritoneum. n=5 or 6. G, The luciferase intensity of each test group was analyzed. Bars, mean ± SD. *p < 0.05; ##, $$, **p < 0.01; ###, $$$, ***p < 0.001.